Cardiovascular risk markers including non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure all improved significantly
Protein intake and nutritional adequacy matter significantly during weight reduction phases
Your provider determines whether peptide therapy may be appropriate
Understanding the GLP-1 consumer The GLP-1 era has given rise to multiple distinct consumer types, each with shared, yet nuanced, nutritional needs: Consumers currently using GLP-1 therapies face unique challenges, including appetite suppression that can make meeting nutritional requirements difficult, potential gastrointestinal side effects and concerns about maintaining muscle mass during weight loss
For example, in the STEP 4 trial, participants who stayed on semaglutide for 68 weeks lost an additional 7.9% of their body weight
That created three problems